Abstract: A composition suitable for use in diagnostic imaging or as a cell killing agent comprising a chelating residue linked via an amide linkage to a poly(alkylene oxide) moiety, said compisition having a molecular weight of at least 4,500; ##STR1## wherein: Z is a chelating residue;Q is a divalent poly(alkylene oxidylene) moiety having a carbon terminus at R and at L;L represents an amide linkage;E.sup.(b) is one or more counterions each having a charge of b;b is an integer from 1, 2 and 3;n is an integer selected from the group 1, 2, 3 and 4;w is zero or an integer from 1 to 5;M.sup.(+a) is a cation, having a charge of +a;a is an integer from 1 to 4;r is 0 or an integer from 1 to 3, provided that when r is 2-3, each M.sup.(+a) can be the same or different cation;d is the total charge on the chelating residue and is an integer from 0 to 10;d+.SIGMA.(b.multidot.w)+.SIGMA.(a.multidot.r)=O; andR is a capping moiety chosen from the group consisting of hydrogen, hydroxyl, C.sub.1 -C.sub.

Abstract: This invention provides therapeutic and diagnostic imaging compositions and methods featuring a polymer comprising units containing a poly(alkylene oxide) moiety linked to the residue of a chelating agent, said polymer having a cytotoxic agent associated therewith.

Abstract: A linear block copolymer comprising units of an alkylene oxide, linked to units of peptide via a linking group comprising a --CH.sub.2 CHOHCH.sub.2 N(R)-- moiety, is useful as an imaging agent, drug, prodrug or as a delivery system for imaging agents, drugs or prodrugs.

Abstract: Described are novel, unsymmetrical oligo-2,6-pyridine complexing agents. Also described are metal chelates and targeting immunoreagents containing such completing agents as well as diagnostic and therapeutic compositions containing such immunoreagents and diagnostic and therapeutic methods of using the immunoreagents.

Abstract: This invention provides compositions useful in MR imaging comprising a polymer comprising units comprising the residue of a chelating agent linked to a poly(alkylene oxide) moiety, the polymer having a paramagetic metal ion associated therewith.

Abstract: The present invention is directed to a method of labeling a protein conjugate with a radionuclide to form a radioconjugate comprising reacting:(a) the radionuclide; and(b) the protein conjugate in an acetate buffer for a time period and under conditions sufficient to form said radioconjugate.Preferably, the protein conjugate is comprised of a complexing agent moiety and a free epsilon amino group-containing protein moiety. The completing agent moiety is preferably a terpyridine analog. The terpyridine analog is preferably TMT.Preferably, the free epsilon amino group-containing protein moiety is an immunoreactive protein. The immunoreactive protein is preferably the monoclonal antibody ING-1.In a preferred embodiment, the protein conjugate is TMT-ING-1, and the radionuclide is .sup.90 Y.In a further preferred embodiment, the radioconjugate is chelated to greater than 98 percent of the radionuclide.

Abstract: A composition suitable for use in diagnostic imaging or as a cell killing agent comprising a chelating residue linked via an amide linkage to a poly(alkylene oxide) moiety, said composition having a molecular weight of at least 4,500; ##STR1## wherein: Z is a chelating residue;Q is a divalent poly(alkylene oxidylene) moiety having a carbon terminus at R and at L;L represents an amide linkage;E.sup.(b) is one or more counterions each having a charge of b;b is an integer from 1, 2 and 3;n is an integer selected from the group 1, 2, 3 and 4;w is zero or an integer from 1 to 5;M.sup.(+a) is a cation, having a charge of +a;a is an integer from 1 to 4;r is 0 or an integer from 1 to 3, provided that when r is 2-3, each M.sup.(+a) can be the same or different cation;d is the total charge on the chelating residue and is an integer from 0 to 10;d+.SIGMA.(b.multidot.w)+.SIGMA.(a.multidot.r)=O; andR is a capping moiety chosen from the group consisting of hydrogen, hydroxyl, C.sub.1 -C.sub.

Abstract: Antibodies that are immunoreactive with interleukin-7 (IL-7) proteins are provided. The anti-IL-7 antibodies may be polyclonal or monoclonal. Certain embodiments are directed to antibodies that are immunoreactive with human IL-7.

Abstract: Mammalian Interleukin-7 proteins (IL-7s), DNAs and expression vectors encoding mammalian IL-7s, and processes for producing mammalian IL-7s as products of cell culture, including recombinant systems, are disclosed.

Abstract: There is disclosed a method of treating microbial infections in microbially infected mammals and a method of augmenting antitumor immunotoxicity in a mammal comprising administering a therapeutically effective amount of IL-7 in a pharmaceutically acceptable carrier. There is further disclosed a method of stimulating macrophages to produce cytokines made by activated macrophages and a method for improving T cell presentation by a macrophage comprising administering a therapeutically effective amount of IL-7. Further, antimicrobial activity of macrophages can be improved by administering a combination of IL-7 and Interferon-.gamma..

Abstract: Aryl-fused- and hetaryl-fused-2,4-diazepines of formula XXXVI, benzodiazocines of formula XXX, benzodiazepines of formula II ##STR1## .delta.-aminoamides of formula III and aryldimethanamines of formula XXXVII ##STR2## wherein A is an aryl or hetaryl ring;R.sup.1 is hydrogen, alkyl, aryl or hetaryl;R.sup.2 is hydrogen, alkyl, substituted alkyl, or aryl;R.sup.3 is alkyl, aryl, aralkyl or heteroatom substituted alkyl or aralkyl;R.sup.4 is hydrogen or alkyl;R.sup.5 is hydrogen, alkyl, aryl or hetaryl;R.sup.6 is hydrogen, alkyl, alkoxy, halogen or a fused benzene ring;R.sup.9 is hydrogen, alkyl, or substituted alkyl; andR.sup.10 is hydrogen, alkyl, or substituted alkyl the invention further relates to processes for the preparation of, pharmaceutical compositions containing, and methods of treating cardiac arrhythmia with the compounds of formulas XXXVI, XXX, II, III, and XXXVII.

Abstract: A compound of the formula ##STR1## wherein: Z is aryl, substituted aryl, phenyl-lower-alkyl, hetero-aryl, substituted heteroaryl, heterocycloalkyl, heterocyclocalkyl-lower-alkyl, hetero-aryl-lower-alkyl wherein one or more hydrogens of aryl and heteroaryl is optionally replaced by A and B;Y is lower cycloalkyl, aryl, phenyl-lower-alkyl, hetero-aryl, heterocycloalkyl, heterocyclocalkyl-lower-alkyl, hetero-aryl-lower-alkyl wherein one or more hydrogens of aryl and heteroaryl is optionally replaced by A and B;X is CONH.sub.2, CONHOH, tetrazole, SO.sub.2 N(R).sub.2, PO(OH).sub.2, CON(R).sub.2, or CONR--CHR--CO--A or CONR--(CHR).sub.n --A;A and B is independently H, OH, OR, halo, CF.sub.3, lower alkyl, N(R).sub.2, CON(R).sub.2, SR, NHSO.sub.2 R, hydroxy-lower-alkyl, NHCOR, NRSO.sub.2 CF.sub.3, OSO.sub.2 CF.sub.3, or CN;R is H, lower-alkyl, phenyl-lower-alkyl, hydroxy-lower-alkyl, CO-lower-alkyl, or CO--(CH.sub.2).sub.n --aryl; andn is 1, 2, or 3, and a pharmaceutically acceptable salt thereof.

Abstract: Disclosed are contrast agents of the formula ##STR1## contained in aqueous compositions and methods for their use in diagnostic radiology of the gastrointestinal tract whereinZ=H, halo, C.sub.1 -C.sub.20 alkyl, cycloalkyl, lower alkoxy, cyano, where the alkyl and cycloalkyl groups can be substituted with halogen or halo-lower-alkyl groups;R=C.sub.1 -C.sub.25 alkyl, cycloalkyl, or halo-lower-alkyl, optionally substituted with halo, fluoro-lower-alkyl, aryl, lower-alkoxy, hydroxy, carboxy, lower-alkoxy carbonyl or lower-alkoxy-carbonyloxy, (CR.sub.1 R.sub.2).sub.p --(CR.sub.3 .dbd.CR.sub.4).sub.m Q, or (CR.sub.1 R.sub.2).sub.p --C.tbd.C--Q;R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are independently lower-alkyl, optionally substituted with halo;x is 1-4;n is 1-5;m is 1-15;p is 1-10; andQ is H, lower-alkyl, lower-alkenyl, lower-alkynyl, lower-alkylene, aryl, or aryl-lower alkyl.

Abstract: A linear block copolymer comprising units of an alkylene oxide, linked to units of peptide via a linking group comprising a --CH.sub.2 CHOHCH.sub.2 N(R)-- moiety, is useful as an imaging agent, drug, prodrug or as a delivery system for imaging agents, drugs or prodrugs.

Abstract: Substituted N-arylmethyl and heterocyclylmethyl-1H-pyrazolo[3,4-b]quinolin-4-amines, pharmaceutical compositions containing them and methods for a) effecting c-GMP-phosphodiesterase inhibition, b) treating heart failure and/or hypertension, c) reversing or reducing nitrate-induced tolerance and d) treating angina pectoris, congestive heart disease and myocardial infarction utilizing them.

Abstract: 2--R.sub.2 --R.sub.4 -substituted-3--R.sub.3 --CO--1--[(C-attached-N-heteryl)-(Alk).sub.n ]--1H-indoles useful as analgesic, anti-rheumatic, anti-inflammatory or anti-glaucoma agents.

Abstract: Disclosed are x-ray contrast compositions for oral or retrograde examination of the gastrointestinal tract comprising an iodophenoxy alkane, iodophenyl alkenylalkyl ether or an iodophenyl alkynylalkyl ether x-ray producing agent in combination with a cellulose derivative in a pharmaceutically acceptable carrier; and methods for their use in diagnostic radiology of the gastrointestinal tract.

Abstract: Substitutued heterocyclylisoquinolinium salts, pharmaceutical compositions containing them and methods for the treatment or prevention of neurodegenerative disorders or neurotoxic injuries utilizing them.

Abstract: 4-R.sup.4 -R.sup.5 -2-Saccharinylmethyl aryl carboxylates, useful in the treatment of degenerative diseases, are prepared by reacting a 4-R.sup.4 -R.sup.5 -2-halomethylsaccharin with an arylcarboxylic acid in the presence of an acid-acceptor.